CareDx Inc
$ 46.69
4.20%
07 Aug - close price
- Market Cap 2,415,471,000 USD
- Current Price $ 46.69
- High / Low $ 46.74 / 44.57
- Stock P/E 22.45
- Book Value 8.27
- EPS 2.08
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE 0.30 %
- 52 Week High 49.76
- 52 Week Low 11.27
About
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Analyst Target Price
$52.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-04-28 | 2026-02-24 | 2025-11-04 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-04 | 2024-07-31 | 2024-05-09 | 2024-02-28 | 2023-11-08 |
| Reported EPS | 0.17 | 0.34 | 0.12 | 0.28 | 0.1 | 0.1 | 0.18 | 0.14 | 0.25 | -0.03 | -0.17 | -0.18 |
| Estimated EPS | 0.06 | 0.13 | -0.01 | 0.14 | 0.12 | 0.07 | 0.1475 | 0.01 | -0.14 | -0.21 | -0.27 | -0.4 |
| Surprise | 0.11 | 0.21 | 0.13 | 0.14 | -0.02 | 0.03 | 0.0325 | 0.13 | 0.39 | 0.18 | 0.1 | 0.22 |
| Surprise Percentage | 183.3333% | 161.5385% | 1300% | 100% | -16.6667% | 42.8571% | 22.0339% | 1300% | 278.5714% | 85.7143% | 37.037% | 55% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDNA
2026-08-08 14:09:39
CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of shares, reducing his total holding by 24%. While this is the largest insider sale in the past year, the shares were sold at a price close to the current market value. Despite no insider purchases in the last year, the company's profitability, growth, and high insider ownership (4.6%) temper concerns from the share sales.
2026-08-08 01:09:39
State Street Corporation has reported a beneficial ownership of 2,468,858 shares of CareDx, Inc. common stock, which represents 4.8% of the class, according to a Schedule 13G SEC filing. All voting and dispositive authority for these shares is shared through affiliated investment adviser entities. The filing indicates that State Street holds less than 5% of CareDx's common stock, classifying it as a passive investment.
2026-08-07 21:40:35
Neil Gagnon and his affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a collective ownership stake of 4.4% in CareDx, Inc. (CDNA) common stock through a SCHEDULE 13G/A SEC filing. Neil Gagnon individually beneficially owns 2,293,464 shares (4.4%), while Gagnon Securities LLC holds 1,629,867 shares (3.2%) and Gagnon Advisors, LLC holds 408,837 shares (0.8%). The filing details the sole and shared voting and dispositive powers over these shares, clarifying that beneficial ownership of client-held securities is disclaimed.
2026-08-07 20:40:35
CareDx, Inc. insider Peter Maag has filed to sell 27,332 shares of Common Stock, which are tied to a stock option exercise dated August 7, 2026. The sale will be executed on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The filing also discloses prior sales by Maag of 46,963 shares on August 5, 2026, valued at $2,178,945.34, and 75,653 shares on August 4, 2026, valued at $3,576,851.19.
2026-08-07 12:40:35
Janus Henderson Group PLC has increased its stake in CareDx, Inc. (NASDAQ:CDNA) by 10.1% to 316,519 shares, valued at approximately $5.5 million. This comes as CareDx reported stronger-than-expected quarterly earnings with $0.37 EPS and revenue of $131.95 million, a 52.2% year-over-year increase. Despite a "Hold" consensus rating and insider selling of over $3.77 million in shares, several analysts have upgraded the stock.
2026-08-07 01:39:26
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack sold 2,688 shares of common stock on August 5, 2026, under a Rule 10b5-1 trading plan established in September 2025. The sales were executed in two tranches at weighted average prices of $46.1492 and $46.75 per share, respectively, totaling approximately $124,000. Following these transactions, Novack directly holds 106,075 shares of CareDx common stock.
